Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.
DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.
DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.
Download Results (CSV)
|
Download Full Data Set (XLS)
| Condition |
Intervention
|
Intervention type
|
Intervention description |
Intervention setting
|
Objective
|
Target population
|
Cost effectiveness
(US$/DALY)
|
Cost effectiveness estimate
(US$)
|
Cost effectiveness range
(US$/DALY)
|
Number of DALYs averted
(hundreds)
|
Number of deaths averted
(hundreds)
|
Quality of cost-effectiveness analysis evidence
|
|
Cervical cancer
|
Chemoradiation therapy |
Personal |
Cisplatin-based chemoradiation regimens on the basis of published and estimated survival. |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
- |
337-31,400 per LYS (USA) |
- |
- |
- |
1 |
|
Cervical cancer
|
Conventional or liquidbased cytology testing |
Personal |
Conventional cytology using the Papanicolaou (Pap) smear and HPV testing every 1 to 10 years; or Liquid-based cytology using the Papanicolaou (Pap) smear and HPV testing every 1 to 5 years |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
- |
126,500 (USA); 162,400 (Thailand) |
- |
- |
- |
2 |
|
Cervical cancer
|
Nationwide Pap screening program based on fiveyear intervals |
Personal |
Nationwide Pap screening program based on five-year intervals |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
- |
769 per YLS (Vietnam) |
- |
- |
- |
2 |
|
Cervical cancer
|
One-visit VIA |
Personal |
Cervix is viewed after the application of an acetic acid solution; screening and treatment conducted during the same visit |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
- |
56 per YLS (Brazil); 54 per YLS (Madagascar); 43 per YLS (Zimbabwe) |
- |
- |
- |
1 |
|
Cervical cancer
|
Three-visit cytology |
Personal |
Cytology sample obtained during the first visit, colposcopy for screen-positive women conducted during the second visit, and treatment provided during the third visit |
Local or district hospital
|
secondary prevention
|
Adults
|
- |
589 per YLS (Brazil); 379 per YLS (Madagascar); 331 per YLS (Zimbabwe) |
- |
- |
- |
1 |
|
Cervical cancer
|
Two-visit HPV testing |
Personal |
HPV DNA testing during the first visit followed by treatment of screen-positive women during the second visit |
Local or district hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
- |
122 per YLS (Brazil); 167 per YLS (Madagascar); 41 per YLS (South Africa); 117 per YLS (Zimbabwe) |
- |
- |
- |
1 |
Download Results (CSV)
|
Download Full Data Set (XLS)